Oruka Therapeutics, Inc. (ORKA) — 8-K Filings

8-K Filings (21)

• Oruka Therapeutics Files 8-K on Officer/Director Changes — Dec 11, 2025 Risk: low
  Oruka Therapeutics, Inc. filed an 8-K on December 11, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointm
• Oruka Therapeutics Files 8-K: Material Agreement & Equity Sales — Sep 22, 2025 Risk: medium
  Oruka Therapeutics, Inc. announced on September 17, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of
• Oruka Therapeutics Files 8-K on Officer/Director Changes — Jul 1, 2025 Risk: low
  Oruka Therapeutics, Inc. filed an 8-K on July 1, 2025, reporting changes in its board of directors and certain officers, along with updates to compensatory arra
• Oruka Therapeutics Files 8-K on Shareholder Vote Matters — Jun 3, 2025 Risk: medium
  Oruka Therapeutics, Inc. filed an 8-K on June 3, 2025, reporting on matters submitted to a vote of security holders as of June 2, 2025. The filing indicates a c
• Oruka Therapeutics Enters Material Definitive Agreement — Feb 5, 2025 Risk: medium
  On February 4, 2025, Oruka Therapeutics, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement, such
• Oruka Therapeutics Signs Material Definitive Agreement — Dec 19, 2024 Risk: medium
  Oruka Therapeutics, Inc. entered into a Material Definitive Agreement on December 17, 2024. The filing does not disclose the specific details of this agreement,
• Oruka Therapeutics Files 8-K on Shareholder Votes — Nov 18, 2024 Risk: low
  Oruka Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting on matters submitted to a vote of security holders as of November 14, 2024. The filing det
• Oruka Therapeutics Appoints New CEO, David Epstein — Oct 4, 2024 Risk: medium
  Oruka Therapeutics, Inc. announced on October 3, 2024, the appointment of Dr. David Epstein as Chief Executive Officer, succeeding Dr. David J. Earp. Dr. Epstei
• Oruka Therapeutics Files 8-K with Key Agreements and Filings — Sep 13, 2024 Risk: medium
  Oruka Therapeutics, Inc. entered into a Material Definitive Agreement on September 11, 2024. The company also reported on unregistered sales of equity securitie
• Oruka Therapeutics Acquired by 03 Life Sciences — Sep 5, 2024 Risk: medium
  Oruka Therapeutics, Inc. announced on August 29, 2024, the completion of its acquisition by 03 Life Sciences. This transaction involved the disposition of asset
• ARCA biopharma to be Acquired by 03 Life Sciences — Aug 27, 2024 Risk: medium
  ARCA biopharma, Inc. announced on August 26, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expect
• ARCA biopharma Files 8-K on Shareholder Votes & Other Events — Aug 23, 2024 Risk: low
  ARCA biopharma, Inc. filed an 8-K on August 22, 2024, reporting on matters submitted to a vote of security holders, other events, and financial statements. The
• ARCA biopharma Files 8-K — Aug 16, 2024 Risk: low
  ARCA biopharma, Inc. filed an 8-K on August 16, 2024, reporting on other events and financial statements. The company, formerly known as NUVELO INC and HYSEQ IN
• ARCA biopharma Files 8-K for Material Agreement — Aug 15, 2024 Risk: medium
  ARCA biopharma, Inc. filed an 8-K on August 15, 2024, reporting an entry into a material definitive agreement and financial statements. The filing details the c
• ARCA biopharma Enters Material Definitive Agreement — Jul 9, 2024 Risk: medium
  On July 3, 2024, ARCA biopharma, Inc. entered into a material definitive agreement. The company, previously known as NUVELO INC and HYSEQ INC, is incorporated i
• ARCA biopharma Appoints New Chief Medical Officer — Apr 23, 2024 Risk: medium
  ARCA biopharma, Inc. announced on April 23, 2024, that its Board of Directors appointed Dr. Michael J. Yaszemski as Chief Medical Officer, effective April 20, 2
• ARCA biopharma Appoints New Chief Medical Officer — Apr 4, 2024 Risk: medium
  ARCA biopharma, Inc. announced on April 4, 2024, that its Board of Directors appointed Dr. Michael J. Yaszemski as Chief Medical Officer, effective April 2, 202
• ARCA biopharma Files 8-K: Agreements, Equity Sales, Control Changes — Apr 3, 2024 Risk: medium
  ARCA biopharma, Inc. filed an 8-K on April 3, 2024, reporting several key events. These include entering into a material definitive agreement, unregistered sale
• ARCA biopharma Enters Material Definitive Agreement — Mar 22, 2024 Risk: medium
  On March 19, 2024, ARCA biopharma, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as th
• ARCA biopharma Files 8-K on Officer/Director Changes, Compensation — Feb 6, 2024
  ARCA biopharma, Inc. filed an 8-K on February 2, 2024, to report changes in its executive compensation arrangements and the departure or election of certain off
• ARCA biopharma Reports Director/Officer Changes, Shareholder Vote — Jan 31, 2024
  ARCA biopharma, Inc. filed an 8-K on January 31, 2024, reporting events that occurred on January 30, 2024. The filing indicates that the company will be submitt

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX